Pharma News

Roche announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer.

Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London.

Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Companys albuterol sulfate inhalation aerosol (90 mcg per actuation). The product is the generic equivalent of PROAIR® HFA (albuterol sulfate inhalation aerosol), a registered trademark of Teva Respiratory LLC.

A new brain implant stands to transform human-computer interaction and expand treatment possibilities for neurological conditions such as epilepsy, spinal cord injury, ALS, stroke, and blindness – helping to manage seizures and restore motor, speech, and visual function. This is done by providing a minimally invasive, high-throughput information link directly to and from the brain.

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

The U.S. Food and Drug Administration today approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first Chimeric Antigen Receptor (CAR) T-cell therapy in the U.S. for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of therapy.

U.S. Food and Drug Administration officially approved a Biologics License Application (BLA) for AVANCE, a processed human nerve scaffold developed by Axogen, for treating peripheral nerve discontinuities in both adults and pediatric patients, including infants aged as young as one month.

Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.